Oral History Review最新文献_第9页

Metastatic Prostate Cancer Manifesting as Cavernous Sinus Syndrome—Case Report and Review of the Literature 以海绵窦综合征表现的转移性前列腺癌病例报告及文献复习

IF 1.1 1区历史学

Oral History Review Pub Date : 2017-01-01 DOI: 10.17925/OHR.2017.13.01.59

B. Kuiper, Aline Babikian, W. Delacruz

引用次数: 0

Answer the Call: Virtual Migration in Indian Call Centers by Aimee Carrillo Rowe, Sheena Malhotra, Kimberlee Pérez (review) 《接听电话:印度呼叫中心的虚拟移民》作者:Aimee Carrillo Rowe, Sheena Malhotra, Kimberlee psamrez

IF 1.1 1区历史学

Oral History Review Pub Date : 2016-09-21 DOI: 10.5860/choice.51-4738

A. LeBoeuf

引用次数: 0

Greater Than Equal: African American Struggles for Schools and Citizenship in North Carolina, 1919–1965. By Sarah Caroline Thuesen. 超越平等:非裔美国人在北卡罗来纳州争取学校和公民身份的斗争，1919-1965。萨拉·卡罗琳·图森著。

IF 1.1 1区历史学

Oral History Review Pub Date : 2016-09-01 DOI: 10.1093/OHR/OHW062

Anna F. Kaplan

引用次数: 0

Editor’s Introduction 编辑器的介绍

IF 1.1 1区历史学

Oral History Review Pub Date : 2016-04-29 DOI: 10.1515/9781503611023-004

Kathryn L. Nasstrom

引用次数: 0

Biosimilars in Oncology 肿瘤学中的生物仿制药

IF 1.1 1区历史学

Oral History Review Pub Date : 2016-01-01 DOI: 10.17925/OHR.2016.12.01.22

A. Zelenetz

{"title":"Biosimilars in Oncology","authors":"A. Zelenetz","doi":"10.17925/OHR.2016.12.01.22","DOIUrl":"https://doi.org/10.17925/OHR.2016.12.01.22","url":null,"abstract":"The escalating cost of cancer care is placing an increasing burden on healthcare systems worldwide, largely a result of expensive biologic therapies. With the patents on many biologics expiring, interest in biosimilars is rising. Biosimilars of biologic agents used for cancer treatment and supportive care are making their appearance in the US; this article therefore aims to increase understanding of the biosimilars concept. Biosimilars are very comparable to their reference products, but because of their size and complexity, are not identical. However, the inherent structural differences between biologics and their reference products may not translate to clinically meaningful differences in efficacy and safety. Biosimilars offer potential cost savings but present a challenge in terms of establishing a regulatory pathway. Regulatory approval requires comparative analytical and clinical studies in order to characterize and demonstrate the absence of clinically meaningful differences between biosimilars and their reference products. Initial approval may not include interchangeability, as additional evidence may be required before a biosimilar can be designated interchangeable with its reference product. A framework for the approval of biosimilars was established by the European Medicines Agency (EMA) in 2006 with the first biosimilar approved in April, 2006. Thus, the experience in Europe provides valuable insights into the use of biosimilars. The widespread use of biosimilars has the potential to reduce healthcare expenditure, as well as improving patient access without compromising patient outcomes, but clinician education and acceptance is crucial.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":"12 1","pages":"22"},"PeriodicalIF":1.1,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67596990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

A Clinical Perspective of Adrenocortical Carcinoma 肾上腺皮质癌的临床观察

IF 1.1 1区历史学

Oral History Review Pub Date : 2016-01-01 DOI: 10.17925/OHR.2016.12.01.47

A. Elfiky

引用次数: 0

The Future of Melanoma Immunotherapy 黑色素瘤免疫治疗的未来

IF 1.1 1区历史学

Oral History Review Pub Date : 2016-01-01 DOI: 10.17925/OHR.2016.12.01.29

N. Khushalani, V. Sondak

引用次数: 0

Cancer Stem Cells and Cancer Stem Cell Inhibitors in Gastrointestinal Cancers 胃肠道肿瘤中的肿瘤干细胞和肿瘤干细胞抑制剂